HAEHaemonetics Corp.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Christopher A. Simon

Location

Massachusetts, USA

Exchange

NYSE

Website

https://haemonetics.com

Summary

Haemonetics Corporation provides medical products and solutions.

Company Info

CEO

Christopher A. Simon

Location

Massachusetts, USA

Exchange

NYSE

Website

https://haemonetics.com

Summary

Haemonetics Corporation provides medical products and solutions.

AI Insights for HAE
5 min read

Quick Summary

Haemonetics Corporation is a U.S.-based medical technology company headquartered in Braintree, Massachusetts. The company provides products and software used in plasma collection, blood center operations, and hospital-based blood management. Its offerings include automated plasma collection devices, disposable collection sets, blood component collection systems, whole blood collection solutions, and specialized hospital technologies. Its main customers include plasma collection centers, blood banks, hospitals, surgical departments, transfusion services, and healthcare systems that need to collect, process, manage, or conserve blood products. The company’s business is focused on improving blood and plasma collection efficiency, reducing waste, supporting patient blood management, and expanding higher-growth hospital applications.

Strengths

•

Haemonetics has a strong position in specialized blood and plasma collection markets, where customer relationships and technical reliability are important.

•

Its plasma franchise benefits from recurring demand for disposables and the broader need for plasma-derived therapies.

•

The company also has improving exposure to hospital blood management, which can offer attractive margins and clinical differentiation.

•

Recent results show meaningful operating leverage, with margin improvement helping offset revenue pressure in some areas.

•

The company’s strategic focus on plasma, apheresis, and hospital markets gives it a clearer direction and may improve capital allocation over time.

Key Risks

•

A key risk is that Haemonetics’ valuation leaves limited room for disappointment if revenue growth, margins, or guidance fall short.

•

Integration risk is also important because acquired technologies must be incorporated into the sales organization, manufacturing base, and customer workflow.

•

Plasma and blood center businesses can be affected by collection volumes, customer concentration, reimbursement dynamics, regulatory requirements, and procurement pressure.

•

Hospital technology adoption may take longer than expected if clinical evidence, budgets, or workflow changes slow purchasing decisions.

What to Watch

During the most recent reported period, Haemonetics beat quarterly expectations and raised fiscal 2026 guidance.
The quarter benefited from stronger performance in plasma and Blood Management Technologies, as well as improved margins.
The Hospital segment continued to expand, helped by strategic initiatives tied to Vivasure and OpSens.
The company also completed the sale of its whole blood assets to GVS for up to $67.8 million, including $45.3 million upfront and potential earnouts.
This transaction supports Haemonetics’ plan to concentrate on plasma, apheresis, and higher-growth hospital opportunities rather than lower-priority legacy assets.

Price Drivers

•

Haemonetics’ stock price is being driven primarily by earnings execution, margin improvement, and confidence in the company’s strategic focus.

•

The company recently beat expectations and raised fiscal 2026 guidance, which supports investor optimism despite mixed revenue trends.

•

Stronger plasma performance, Blood Management Technologies growth, and hospital expansion are positive drivers because they suggest the company can grow in higher-value areas.

•

Valuation is also a major factor because the stock trades at elevated multiples, including a price-to-earnings ratio above 50 and an EV-to-EBITDA ratio above 25 based on the provided data.

•

The market is likely to react strongly to any changes in guidance, acquisition integration progress, bookings, debt levels, and evidence that revenue growth can improve after expected near-term declines.

Recent News

•

Recent news indicates that Haemonetics beat Q3 expectations and raised fiscal 2026 guidance, supported by stronger plasma and Blood Management Technologies performance.

•

The company also reported a fiscal Q4 2025 adjusted EPS beat, with adjusted EPS of $1.24 rising 37.8% despite a revenue decline to $330.6 million.

•

Hospital sales grew in that period, while Plasma and Blood Center were weaker, making margin improvement especially important.

•

Haemonetics completed the sale of its whole blood assets to GVS for up to $67.8 million, reinforcing its strategy to focus on plasma, apheresis, and hospital markets.

•

Some of the provided news items discuss hereditary angioedema companies rather than Haemonetics Corporation, so they appear unrelated to the HAE stock ticker and should not be treated as company-specific developments.

Market Trends

•

The medical equipment and healthcare technology market is being shaped by hospital cost pressure, demand for workflow efficiency, and the need to demonstrate clear clinical value.

•

Plasma collection remains an important market because plasma-derived therapies support treatment of serious immune, neurological, hematological, and other conditions.

•

Blood center markets can be more mature and price-sensitive, which encourages companies like Haemonetics to focus on higher-growth hospital and specialty areas.

•

Healthcare stocks have recently faced pressure, and investors are scrutinizing companies with slow growth or high valuations more aggressively.

•

At the same time, companies that can deliver recurring revenue, margin expansion, software integration, and differentiated clinical outcomes may continue to receive premium valuations.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on HAE

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar

Haemonetics jumped because of increased plasma product usage

Haemonetics jumped because of increased plasma product usage

surger more than 17% after news that CSL Plasma had expanded the use of the company’s products. I know that this may not sound like much but think about it this way. In the broader marker, mostly the entire market shifts because of AI or oil. Pharma stocks are untouched and depend on the progress in healthcare. Should be a good idea to invest in some pharma stocks. What do you think?

No more topics to show